Loading
Adding pembrolizumab to first-line chemotherapy, with or without bevacizumab, lengthened survival in advanced cervical cancer, the first improvement in the disease since bevacizumab was added seven years earlier.
Phase 3 placebo-controlled trial of 617 patients with persistent, recurrent or metastatic cervical cancer randomised to pembrolizumab or placebo with platinum-paclitaxel chemotherapy, with bevacizumab at investigator discretion.
In the PD-L1 combined positive score 1 or more population, median overall survival was not reached versus 16.3 months at the first analysis (hazard ratio 0.64) and 28.6 versus 16.5 months on update; progression-free survival was 10.4 versus 8.2 months.
Pembrolizumab plus chemotherapy with bevacizumab is the first-line standard for recurrent or metastatic cervical cancer with PD-L1 expression, which covers about nine in ten patients.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, Pembrolizumab.
Shares KEYNOTE-826, Pembrolizumab.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, Pembrolizumab.
Shares Recurrent or metastatic cervical cancer, Pembrolizumab.
Shares Recurrent or metastatic cervical cancer, Pembrolizumab.